Shanghai Model Organisms Center, Inc. News

Nanmo Biotech (688265): Revenue was basically flat year-on-year, and the research side gradually recovered

Nov 7, 2023 07:36

Nanmo Biotech (688265): Revenue side grew steadily and turned loss into profit in the second quarter

國聯證券Aug 31, 2023 11:16

Nanmo Biotech (688265): Profit under pressure for a short time, optimistic about the recovery of demand on the research side

長江證券Aug 30, 2023 00:00

Southern Model Biology (688265): Revenue is steadily recovering, R&D planning ahead

長江證券Nov 2, 2022 00:00

Southern Model Biology (688265): Revenue improved month-on-month, high investment and profits are under pressure

興業證券Oct 31, 2022 00:00

Southern model biology (688265): the impact of the epidemic on sustained short-term performance pressure

長江證券Sep 6, 2022 00:00

South Model Biology (688265): performance under short-term pressure and long-term growth logic unchanged

興業證券Aug 31, 2022 16:41

Nanmo Biotech (688265) Company Brief Review Report: Affected by the epidemic, Nanmo Biotech's performance is under pressure in the short term and is optimistic about the company's medium- to long-term development

首創證券Aug 31, 2022 00:00

Southern model biology (688265): the epidemic affects the current performance and is expected to recover significantly in the second half of the year.

德邦證券Aug 31, 2022 00:00

South Model Biology (688265): epidemic affects short-term performance and expects performance recovery

國聯證券Aug 31, 2022 00:00

Southern model biology (688265): the impact of the epidemic on sustained short-term performance pressure

長江證券Jul 14, 2022 00:00

Southern Model Biology (688265): Emerging Stars in the Model Biology Industry

德邦證券May 24, 2022 00:00

South Model Biology (688265): the rapid development of core business does not affect the high growth trend in the short term.

興業證券May 3, 2022 00:00

Southern model biology (688265): short-term performance fluctuations caused by expected revenue from the epidemic

長江證券Apr 30, 2022 00:00

Southern Model Biology (688265): Steady increase in revenue, equity incentives show confidence

華安證券Apr 29, 2022 00:00

Nanmo Biotech (688265): The technology platform is fully expected to become the leading model animal in China

Mar 29, 2022 00:00

Nanmo Biotech (688265): Leading technology-leading “live reagent” supplier for model animals

華安證券Mar 3, 2022 14:56

South Model Biology (688265) 2021 performance KuaiBao comments: multi-line acceleration end-to-end integrated layout model animal service

興業證券Feb 27, 2022 00:00

Southern moth organisms (688265): Featured upstream life science leaders in animals that are deeply involved in genetic modification models

興業證券Jan 28, 2022 10:06